Preview

User

Not a user? Register with this site Forgot your password?

Problems of Endocrinology

Advanced search

The role of insulin sensitizers and calcium plus vitamin D3 preparations in the combined treatment of polycystic ovary syndrome

https://doi.org/10.14341/probl201359149-56

Abstract

Polycystic ovary syndrome (PCOS) is a multifactor diseases associated with genetic predisposition to this pathology that develops under effect of the unfavourable environmental factors. One of the main causes that provokes hyperandrogenic anovulation in PCOS is pathologic insulin resistance arising in the predisposed subjects as a result of supranormal dietary intake and low physical activity. Such factors as calcium and vitamin D insufficiency, besides other metabolic disturbances and ovarian dysfunction, play an important role in the energy imbalance associated with PCOS. Moreover, these factors along with obesity and insulin resistance are responsible for a broad spectrum of PCOS complications. There is a wealth of data suggesting the positive influence of insulin sensitizers (in the first place, metformin) on the ovarian function and their prophylactic effect on the risk of PCOS. The effectiveness of therapy using such micronutrients as calcium and vitamin D is less known. However, the results of the relevant studies give evidence of good prospects for their application for the prevention of PCOS and its consequences.

About the Author

I V Kuznetsova



References

1. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS society. Fertil Steril 2009; 91: 456-488.

2. Escobar-Morreale H.F. Polycystic ovary syndrome: treatment strategies and management. Exp Opin Pharmacother 2008; 9: 17: 2995-3008.

3. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.

4. Cussons A.J., Stuckey B.G., Watts G.F. Cardiovascular disease in the polycystic ovary syndrome: new insight and perspectives. Atherosclerosis 2006; 185: 227-239.

5. Hahn S., Haselhorst U., Tan S., Quadbeck B., Schmidt M., Roesler S., Kimmig R., Mann K., Janssen O.E. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabet 2006; 114: 577-583.

6. Манухин И.Б., Геворкян М.А., Чагай Н.Б. Ановуляция и инсулинорезистентность. М: ГЭОТАР-Медиа 2006; 54-83.

7. Douchi T., Kuwahata R., Yamamoto S., Oki T. Relationship of upper body to menstrual disorders. Acta Obstet Gynecol Scand 2002; 81: 147-150.

8. Серов В.Н., Кан Н.И. Ожирение и репродуктивное здоровье. Пробл репрод 2004; 3: 16-20.

9. Дедов И.И., Мельниченко Г.А. Ожирение: этиология, патогенез, клинические аспекты. М: МИА 2004; 456.

10. Чернуха Г.Е. Современные представления о синдроме поликистозных яичников. Гинекология 2002; 4: 174-175.

11. Pasquali R., Pelusi C., Genghini S. Obesity and reproductive disorders in women. Hum Reprod Update 2003; 9: 4: 359-372.

12. Patel S.M., Ratcliffe S.J., Reilly M.P. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metabol 2009; 94: 12: 4776-4784.

13. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metabol 2007; 92: 6: 2017-2029.

14. Plum L.A., DeLuca H.F. The functional metabolism and molecular biology of vitamin D action. In: Vitamin D: Physiology, Molecular Biology, and Clinical Applications. Ed. M.F. Holick. 2-nd ed. New York: Humana Press 2010; 61-97.

15. Ullah G., Machaca K. Modeling Ca2+ signaling differentiation during oocyte maturation. Cell Calcium 2007; 42: 556-564.

16. Zemel M.B. Role of calcium and dairy products in energy partitioning and weight managment. Am J Clin Nutr 2004; 79: 907-912.

17. Young K.A., Engelman C.D., Langefeld C.D., Hairston K.G., Haffner S.M., Bryer-Ash M. Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metabol 2009; 94: 9: 3306-3313.

18. Panidis D., Balaris C., Farmakiotis D., Rousso D., Kourtis A., Balaris V., Katsikis I., Zournatzi V., Diamanti-Kandarakis E. Serum parathyreoid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 2005; 51: 1691-1697.

19. Farshchi H., Ranel A., Lovel A., Kennedy R.L. Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. J Obstet Gynaecol 2007; 27: 8: 762-773.

20. Cheang K.I., Nestler J.E. Should insulin-sensitazing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 2004; 8: 440-447.

21. Baillargeon J.P. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Invest 2005; 6: 1012-1022.

22. Legro R.S., Barnhart H.X., Shlaff W.D. Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356: 551-566.

23. Pesant M.H., Baillargeon J.P. Ovulation induction in polycystic ovary syndrome - how do metformin and clomifene citrate compare? Nat Clin Pract Endocrin Metabol 2007; 3: 512-513.

24. Zain M.M., Jamaluddin R., Ibrahim A., Norman R.J. Comparison of clomiphene citrate, metformin, oor the combination of both for the first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2009; 91: 2: 514-521.

25. Firouzabadi R., Aflatoonian A., Modaressi S., Sekhavat L., Taheri S.M. Therapeutic effects of calcium &vitamin D supplementation in women with PCOS. Complement Therap Clin Practice 2012; 18: 85-88.

26. Rashidi B., Haghollahi F., Shariat M., Zayerri F. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol 2009; 48: 2: 142-147.

27. Orio F.J., Palomba S., Cascella T. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2004; 89: 4588-4593.

28. Wulffele M.G., Kooy A., Lehert P. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003; 254: 455-463.

29. Halman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes: the UKPDS experience. New Engl J Med 2008; 359: 15: 11577-1589.

30. Cussons A.J., Watts G.F., Mori T.A., Stuckey B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metabol 2009; 94: 10: 3842-3848.

31. Muscogiuri G., Sorice G.P., Prioletta A. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity 2010; 18: 1906-1910.

32. Reid I.R., Horne A., Mason B., Ames R., Bava U., Gamble G.D. Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. J Clin Endocrinol Metabol 2005; 90: 3824-3829.

33. Hsia J., Heiss G., Ren H. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854.

34. Bolland M.J., Barber P.A., Doughty R.N., Mason B. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008; 336: 262-266.

35. Ginde A.A., Scragg R., Schwartz R.S., Camargo C.A. Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all cause mortality in older U.S. adults. J Am Geriatr Soc 2009; 57: 9: 1595-1603.

36. Dobnig H., Pilz S., Scharnagl H. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 12: 1340-1349.

37. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 16: 1730-1737.

38. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813-2818.

39. Mathieu C., Gysemans C., Giulietti A. Vitamin D and diabetes. Diabetologia 2005; 48: 1247-1257.

40. Chonchol M., Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 2007; 71: 134-139.

41. Liu E., Meigs J.B., Pittas A.G., Economus C.D., McKeown N.M., Booth S.L., Jacques P.F. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139: 329-334.


Review

For citations:

Kuznetsova I.V. The role of insulin sensitizers and calcium plus vitamin D3 preparations in the combined treatment of polycystic ovary syndrome. Problems of Endocrinology. 2013;59(1):49-56. https://doi.org/10.14341/probl201359149-56

Views: 1184


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)